Aclaris Therapeutics, Inc. (ACRS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Aclaris Therapeutics, Inc. (ACRS) is up 46.8% since the beginning of the year. At $4 per share, ACRS is trading 14.2% below its 52-week high of $5. Investors who bought $1,000 worth of ACRS shares 5 years ago would now be looking at an investment worth $203.

Aclaris Therapeutics, Inc. (ACRS) has returned 46.84% so far this year and 200.68% over the past 12 months. Over the last ten years, ACRS has returned -14.10% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Oct 7, 2015, ACRS's average daily return is +0.18%, while the average monthly return is +3.24%. At this rate, an investment would double in approximately 1.8 years.

Historically, 48% of months were positive and 52% were negative. The best month was Jan 2021 with a return of +220.7%, while the worst month was Nov 2023 at -82.4%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ACRS closed higher 47% of trading days. The best single day was Jan 19, 2021 with a return of +220.2%, while the worst single day was Nov 13, 2023 at -86.4%.

Aclaris Therapeutics, Inc. has an annualized alpha of 35.32%, beta of 0.98, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since October 08, 2015.

• This stock participated in 132.90% of S&P 500 Index downside but only 43.03% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ACRS ranks 91 for risk / return — in the top 91% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aclaris Therapeutics, Inc. was 98.05%, occurring on Nov 13, 2023. The portfolio has not yet recovered.

The current Aclaris Therapeutics, Inc. drawdown is 86.60%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aclaris Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aclaris Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.